WE CARE
ABOUT YOU
Aorta Laboratories Pvt. Ltd. is a specialty generic pharmaceutical company in India with global revenues exceeding USD 6 million. We are committed to improving patient access to high-quality, affordable medicines through continuous innovation and responsible manufacturing practices. Backed by a portfolio of over 22 manufactured products and robust production facilities, we deliver trusted pharmaceutical solutions to healthcare professionals and patients across more than 100 cities nationwide.
Overview
Aorta Laboratories Private Limited is an unlisted private pharmaceutical company incorporated on 05 December 2011 and registered in Mumbai City, Maharashtra. The Company is classified as a Private Limited entity and operates with an authorized share capital of INR 10.00 lakh and a paid-up capital of INR 10.00 lakh.
Aorta Laboratories is actively engaged in the development, manufacturing, and distribution of specialty generic pharmaceutical products, with a clear focus on quality, affordability, and regulatory compliance. Our operations are supported by a growing portfolio of manufactured products and established facilities designed to meet industry standards and healthcare expectations.
The Company is led by its directors, Vikash Raj and Neelam Kumari, who provide strategic direction and governance to ensure sustainable growth, ethical practices, and long-term value creation. Under their leadership, Aorta Laboratories continues to strengthen its presence across multiple cities in India, supplying reliable pharmaceutical solutions trusted by healthcare professionals and patients alike.
The registered office of Aorta Laboratories Private Limited is located in Andheri (West), Mumbai, Maharashtra. As an active company, we remain committed to continuous improvement, operational excellence, and contributing meaningfully to the healthcare ecosystem in India.
Financial Highlights
Aorta Laboratories Private Limited operates with an authorized share capital of INR 10.00 lakh, reflecting a stable and well-defined capital structure. As of the latest filings, the Company has a paid-up capital of INR 3.00 lakh, representing 30.000002% of its authorized capital.
The Company has maintained statutory compliance, with its most recent Annual General Meeting (AGM) held on 30 November 2021. In accordance with records available from the Ministry of Corporate Affairs (MCA), the latest balance sheet of Aorta Laboratories Private Limited was filed for the financial year ending 31 March 2021, underscoring its commitment to regulatory transparency and corporate governance.
| CIN | U24233MH2011PTC224638 |
| Date of Incorporation | 05 Dec, 2011 |
| Status | Active |
| Company Category | Company limited by Shares |
| Company Sub-category | Non-govt company |
| Company Class | Private |
| Business Activity | Manufacturing (Metals & Chemicals, and products thereof) |
| Authorized Capital | 10.0 lakhs |
| Paid-up Capital | 3.0 lakhs |
| Paid-up Capital % | 30.000002 |
| Registrar Office City | Mumbai |
| Registered State | Maharashtra |
| Registration Number | 224638 |
| Registration Date | 05 Dec, 2011 |
| Listing Status | Unlisted |
| AGM last held on | 30 Sep, 2017 |
| Balance Sheet last updated on | 31 Mar, 2017 |
Board of Directors
Aorta Laboratories Private Limited is governed by a two-member Board of Directors and does not have any reported Key Management Personnel at present. The Board provides strategic oversight and ensures adherence to sound corporate governance practices.
The longest-serving directors on the Board are Vikash Raj and Neelam Kumari, both of whom were appointed on 18 July 2018. Each has served the Company for over four years and nine months, contributing continuity, stability, and experienced leadership to the organization.
Among the current directors, Vikash Raj holds the highest number of external directorships, serving on the boards of two companies. Through its directors, Aorta Laboratories Private Limited maintains a professional association with one other corporate entity, supporting governance alignment and industry engagement.